Prevalence of comorbid asthma in COVID-19 patients

Butler, Marcus W.; O’Reilly, Aine; Dunican, Eleanor M.; Mallon, Patrick; Feeney, Eoin R.; Keane, Michael P.; McCarthy, Cormac

doi:10.1016/j.jaci.2020.04.061

Cited by 33 publications

(28 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of asthma among adult COVID-19 patients shows marked regional differences, with an incidence lower than the general population in China (0.9%), 24 Italy (1.96% and 1.92%), 25 Sweden (1.8% and 2.6%), 26 Russia (1.8%), 27 and Brazil (1.5%), 28 but a higher incidence in Spain (5.2%), 29 Ireland (8.8%), 30 the UK (17.9%), 31 and the USA (7.4% 14%). 32 , 33 Prevalence data on asthma among pediatric COVID-19 patients are quite scarce.…”

Section: Discussionmentioning

confidence: 98%

Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019

Beken

Öztürk

Aygün

et al. 2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019

Beken

Öztürk

Aygün

et al. 2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

“…The prevalence of asthma among the COVID-19 patients was 2.9% in this study, which is similar to that among the general South Korean population (1.6% to 2.2%) [ 13 – 15 ]. Underlying asthma is reported to account for 0.9–17% of patients hospitalised with COVID-19 in other countries [ 1 , 7 , 8 ]. Some studies have reported that the prevalence of asthma in the COVID-19 population is lower than that expected in the general population [ 16 , 17 ], however other studies showed that asthma was reported in up to 27% cases [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

“…We can assume underlying asthma might affect the clinical outcomes of COVID-19 infection, since respiratory viruses broadly can increase the risk of asthma exacerbation and death. In previous studies, underlying asthma is reported to account for 0.9–17% of hospitalised patients with COVID-19 [ 1 , 7 , 8 ]. However, the importance of underlying asthma is still overlooked in many COVID-19 studies, and there are currently no studies determining whether asthma is a risk factor for poor prognosis of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Effect of asthma and asthma medication on the prognosis of patients with COVID-19

et al. 2020

View full text Add to dashboard Cite

BackgroundCoronavirus disease (COVID-19) has rapidly spread worldwide. However, the effects of asthma, asthma medication, and asthma severity on the clinical outcomes of COVID-19 have not yet been established.MethodsThe study included 7590 de-identified patients, who were confirmed to have COVID-19 using the severe acute respiratory syndrome-coronavirus-2 RNA–polymerase chain reaction tests conducted up to 15th May 2020; and we used the linked-medical claims data provided by the Health Insurance Review and Assessment Service. Asthma and asthma severity (step suggested by GINA) was defined using the diagnostic code and history of asthma medication usage.ResultsAmong 7590 COVID-19 patients, 218 (2.9%) had underlying asthma. The total medical cost associated with COVID-19 patients with underlying asthma was significantly higher than that of other patients. Mortality rate for COVID-19 patients with underlying asthma (7.8%) was significantly higher than that of other patients (2.8%; p<0.001). However, asthma was not an independent risk factor for the clinical outcomes of COVID-19 after adjustment. Asthma medication use and asthma severity also did not affect the clinical outcomes of COVID-19. However, use of oral short-acting β2-agonists (SABA) was an independent factor to increase the total medical cost burden. Patients with step 5 asthma showed significant prolonged admission duration than those with step 1 asthma in both univariate and multivariate analysis.ConclusionsAsthma led to poor outcomes of COVID-19; however, underlying asthma, use of asthma medication, and asthma severity were not independent factors for poor clinical outcomes of COVID-19, generally.

show abstract

“…16 However, subsequent reports from around the world have suggested that asthma may not be risk factor for severe COVID-19, including hospitalization and death. 6,8,[17][18][19] However, these reports have largely been limited by several factors including the inclusion of other chronic pulmonary conditions (e.g. COPD) in populations studied, conditioning on patients who were hospitalized with COVID-19, 18 and/or not accounting for secular changes in COVID-19 testing criteria.…”

Section: Discussionmentioning

confidence: 99%

“…4,5 While current data from the COVID-19 pandemic is limited, there have been conflicting reports on the association of asthma to severity of COVID-19. [6][7][8] Whether asthma is associated with severe clinical outcomes in COVID-19 is of high clinical importance to the over 20 million adult patients with asthma in the US. 9 We therefore performed a matched cohort study to understand the relation of asthma to COVID-19 disease severity in patients with SARS-CoV-2 infection in a large Boston-based health care system.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 severity in asthma patients: A multi-center matched cohort study

Robinson

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: The evidence pertaining to the effects of asthma on Coronavirus disease 2019 outcomes has been unclear. To improve our understanding of the clinically important association of asthma and Coronavirus disease 2019. Methods: A matched cohort study was performed using data from the Mass General Brigham Health Care System (Boston, MA). Adult (age ≥ 18 years) patients with confirmed Coronavirus disease 2019 and without chronic obstructive pulmonary disease, cystic fibrosis, or interstitial lung disease between March 4, 2020 and July 2, 2020 were analyzed. Up to 5 non-asthma comparators were matched to each asthma patient based on age (within 5 years), sex, and date of positive test (within 7 days). The primary outcomes were hospitalization, mechanical ventilation, and death, using multivariable Cox-proportional hazards models accounting for competing risk of death, when appropriate. Patients were followed for these outcomes from diagnosis of Coronavirus disease 2019 until July 2, 2020. Results: Among 562 asthma patients, 199 (21%) were hospitalized, 15 (3%) received mechanical ventilation, and 7 (1%) died. Among the 2686 matched comparators, 487 (18%) were hospitalized, 107 (4%) received mechanical ventilation, and 69 (3%) died. The adjusted Hazard Ratios among asthma patients were 0.99 (95% Confidence Internal 0.80, 1.22) for hospitalization, 0.69 (95% Confidence Internal 0.36, 1.29) for mechanical ventilation, and 0.30 (95% Confidence Internal 0.11, 0.80) for death. Conclusions: In this matched cohort study from a large Boston-based healthcare system, asthma was associated with comparable risk of hospitalization and mechanical ventilation but a lower risk of mortality.

show abstract

Prevalence of comorbid asthma in COVID-19 patients

Cited by 33 publications

References 4 publications

Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019

Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019

Effect of asthma and asthma medication on the prognosis of patients with COVID-19

COVID-19 severity in asthma patients: A multi-center matched cohort study

Contact Info

Product

Resources

About